By: Rob Volansky, Shenaz Bagha
Elevations in liver enzymes were “uncommon” among a U.S. cohort treated with avacopan for ANCA-associated vasculitis , with 0.8% developing drug-induced liver injury, according to findings published in Arthritis & Rheumatology.